



Revance Therapeutics  
 Investor Relations Department  
 7555 Gateway Boulevard  
 Newark, CA 94560  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

<b>NASDAQ: RVNC</b>	
Last Trade:	24.15
Trade Time:	4:00 PM ET Jul 24, 2017
Change:	0.40 <span style="color: green;">↑</span> (+1.684%)
Day Range	23.00 - 24.20
52-Week Range	12.35 - 28.30
Volume	230,683

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jul 24, 2017*  
[Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017](#)
- Jun 15, 2017*  
[Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery](#)
- Jun 5, 2017*  
[Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial](#)
- Jun 1, 2017*  
[Revance to Participate in Upcoming Investor Conferences](#)
- May 18, 2017*  
[Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial](#)

## Upcoming Events [\[ View all \]](#)

- Aug 3, 2017 4:30 PM ET*  
[Revance Therapeutics 2017 Second Quarter Financial Results](#)
- Financials [\[ View all \]](#)**  
[First Quarter Financial Results](#)
- Feb 28, 2017*  
[Annual Report \(10-K\)](#)
- Mar 24, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 5, 2016*  
[Quarterly Report \(10-Q\)](#)